Chemomab Therapeutics Ltd
NASDAQ:CMMB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Chemomab Therapeutics Ltd
Total Liabilities & Equity
Chemomab Therapeutics Ltd
Total Liabilities & Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities & Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Chemomab Therapeutics Ltd
NASDAQ:CMMB
|
Total Liabilities & Equity
$13.8m
|
CAGR 3-Years
-32%
|
CAGR 5-Years
2%
|
CAGR 10-Years
N/A
|
|
|
Kamada Ltd
NASDAQ:KMDA
|
Total Liabilities & Equity
$378.7m
|
CAGR 3-Years
6%
|
CAGR 5-Years
12%
|
CAGR 10-Years
14%
|
|
|
Enlivex Therapeutics Ltd
NASDAQ:ENLV
|
Total Liabilities & Equity
$20.9m
|
CAGR 3-Years
-34%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-1%
|
|
|
Urogen Pharma Ltd
NASDAQ:URGN
|
Total Liabilities & Equity
$200.5m
|
CAGR 3-Years
14%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
|
Entera Bio Ltd
NASDAQ:ENTX
|
Total Liabilities & Equity
$17.4m
|
CAGR 3-Years
4%
|
CAGR 5-Years
15%
|
CAGR 10-Years
N/A
|
|
|
Pluri Inc
NASDAQ:PLUR
|
Total Liabilities & Equity
$30.6m
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-6%
|
|
Chemomab Therapeutics Ltd
Glance View
Chemomab Therapeutics Ltd. operates as a clinical-stage biotech company. The firm specializes in the development of patient oriented targeted therapy for the treatment of a wide range of cancers. Its therapeutic and diagnostic technology, BC-819, constitutes a search paradigm for the targeted destruction of cancer cells with no effect on surrounding tissue and no observed side effects for long-term, safe treatment and prevention of cancer. The patient oriented targeted therapy approach is based on the identification of particular genes that are expressed only in tumors.
See Also
What is Chemomab Therapeutics Ltd's Total Liabilities & Equity?
Total Liabilities & Equity
13.8m
USD
Based on the financial report for Dec 31, 2025, Chemomab Therapeutics Ltd's Total Liabilities & Equity amounts to 13.8m USD.
What is Chemomab Therapeutics Ltd's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 5Y
2%
Over the last year, the Total Liabilities & Equity growth was -19%. The average annual Total Liabilities & Equity growth rates for Chemomab Therapeutics Ltd have been -32% over the past three years , 2% over the past five years .
